Novartis lowered a major inherited heart-risk marker by 78%. Why did patients not benefit?
Novartis cut Lp(a) by 78% with pelacarsen but failed to reduce cardiovascular events, raising the stakes for Amgen and Eli Lilly.
Pharma & Biotech
Features & Analysis
AstraZeneca and Amgen report 58% lower death risk with IMFINZI and tarlatamab in small-cell lung cancer
AstraZeneca PLC (NASDAQ: AZN) and Amgen Inc. (NASDAQ: AMGN) have reported Phase 3 findings showing that IMFINZI (durvalumab) combined with IMDELLTRA (tarlatamab-dlle) reduced the hazard of death by 58% compared with IMFINZI alone as first-line maintenance treatment for extensive-stage small-cell lung cancer. Presented at the European Society for Medical Oncology Congress 2026 on October 24
Pharma & Biotech
Sling Therapeutics reports 82% sustained response with linsitinib in thyroid eye disease
Sling reports 82% sustained response among linsitinib responders after 48 weeks off therapy. See why Phase 3 ORBIT is the next critical test.
Pharma & Biotech
Teva wins FDA approval for DEGEVMA biosimilar across all Xgeva indications
FDA approves Teva’s DEGEVMA as an Xgeva biosimilar across oncology bone-disease indications, expanding its U.S. denosumab portfolio.
Pharma & Biotech
Bristol Myers Squibb sues Amgen over Opdivo biosimilar as $10bn franchise nears patent cliff
Bristol Myers Squibb and Ono Pharmaceutical are suing Amgen over seven patents tied to its proposed Opdivo biosimilar ABP 206, opening an important legal battle around a cancer drug that generated more than $10 billion in 2025.
Pharma & Biotech
Amgen removes an Imdelltra treatment burden just as its DLL3 therapy approaches a much larger first-line opportunity
The FDA has reduced monitoring requirements around the first two Imdelltra doses, lowering an important logistical burden days after Amgen reported positive Phase 3 survival data in first-line extensive-stage small cell lung cancer.
Pharma & Biotech
GSK’s Ris-Rez cuts death risk 54% in relapsed small cell lung cancer as ADC pipeline gains weight
GSK’s licensed B7-H3 antibody-drug conjugate Ris-Rez delivered median survival of 18.5 months versus 10.3 months with topotecan in a Chinese Phase 3 study, strengthening the company’s case for global development.
Pharma & Biotech
Only about 40% of extensive-stage SCLC patients reach second-line therapy. Amgen and AstraZeneca are moving Imdelltra earlier
Amgen’s Phase 3 DeLLphi-305 trial met its primary overall survival endpoint with Imdelltra plus Imfinzi as first-line maintenance in extensive-stage small cell lung cancer.
Pharma & Biotech
Repatha cut deaths by 20% in high-risk patients who had never had a heart attack or stroke
A prespecified VESALIUS-CV analysis found a 20% reduction in mortality with Amgen’s Repatha among more than 12,000 high-risk adults without a previous heart attack or stroke, strengthening the case for intensive LDL lowering before the first major cardiovascular event.
Pharma & Biotech
TEZSPIRE clears every major Phase 3 hurdle in EoE. Could blocking TSLP reshape another disease?
Amgen and AstraZeneca say TEZSPIRE achieved both co-primary and all key secondary endpoints in the Phase 3 CROSSING study, potentially extending the TSLP-blocking biologic into eosinophilic esophagitis.